Drugs / DWJ1464
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04477369 | Aug 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT06272630 | Feb 2023 → Mar 2024 | liver disorder | Daewoong Pharmaceutical Co. LTD. | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWJ1464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06272630 ↗ |